Aerovate Therapeutics (AVTE) Competitors $11.14 +0.34 (+3.15%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. NAGE, AUPH, ELVN, ABCL, WVE, VERV, PAHC, AKBA, COLL, and NTLAShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Niagen Bioscience (NAGE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Niagen Bioscience Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics WAVE Life Sciences Verve Therapeutics Phibro Animal Health Akebia Therapeutics Collegium Pharmaceutical Intellia Therapeutics Niagen Bioscience (NASDAQ:NAGE) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations. Does the media favor NAGE or AVTE? In the previous week, Niagen Bioscience had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Niagen Bioscience and 0 mentions for Aerovate Therapeutics. Niagen Bioscience's average media sentiment score of 0.34 beat Aerovate Therapeutics' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Overall Sentiment Niagen Bioscience Neutral Aerovate Therapeutics Neutral Which has better valuation & earnings, NAGE or AVTE? Niagen Bioscience has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$99.60M10.05$8.55M$0.1774.76Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-6.55 Do analysts rate NAGE or AVTE? Niagen Bioscience currently has a consensus price target of $19.50, indicating a potential upside of 53.42%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Niagen Bioscience is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NAGE or AVTE more profitable? Niagen Bioscience has a net margin of 13.07% compared to Aerovate Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 19.06% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience13.07% 19.06% 12.20% Aerovate Therapeutics N/A -90.19%-77.47% Do institutionals & insiders have more ownership in NAGE or AVTE? 15.4% of Niagen Bioscience shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, NAGE or AVTE? Niagen Bioscience has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. SummaryNiagen Bioscience beats Aerovate Therapeutics on 14 of the 15 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$322.89M$790.73M$5.53B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E Ratio-3.731.1327.5220.22Price / SalesN/A226.97421.02118.64Price / CashN/A23.4436.8958.07Price / Book2.816.298.045.67Net Income-$75.52M-$27.73M$3.18B$249.13M7 Day Performance21.22%1.82%2.90%3.28%1 Month Performance54.51%9.90%3.70%5.55%1 Year Performance-80.23%10.79%36.15%21.12% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$11.14+3.1%N/A-81.2%$322.89MN/A-3.7320High Trading VolumeNAGENiagen Bioscience1.3647 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.06B$99.60M80.24120AUPHAurinia Pharmaceuticals3.251 of 5 stars$7.83+0.8%$11.50+46.9%+38.3%$1.05B$235.13M27.96300ELVNEnliven Therapeutics2.5174 of 5 stars$20.29-4.7%$39.60+95.2%-4.1%$1.05BN/A-10.5750Analyst ForecastAnalyst RevisionHigh Trading VolumeABCLAbCellera Biologics2.4905 of 5 stars$3.33-2.3%$8.33+150.3%+40.4%$1.02B$28.83M-5.95500WVEWAVE Life Sciences4.372 of 5 stars$6.96+5.9%$20.50+194.5%+31.0%$1.01B$108.30M-8.29240VERVVerve Therapeutics3.436 of 5 stars$11.11+0.5%$14.75+32.8%+118.4%$985.92M$32.33M-5.27110High Trading VolumePAHCPhibro Animal Health3.6387 of 5 stars$24.46+2.4%$20.80-15.0%+63.3%$967.94M$1.02B31.361,940AKBAAkebia Therapeutics4.2685 of 5 stars$3.64-1.1%$6.75+85.4%+280.9%$966.50M$160.18M-17.33430Positive NewsInsider TradeCOLLCollegium Pharmaceutical4.1408 of 5 stars$29.88+0.2%$43.75+46.4%-6.1%$958.49M$631.45M24.49210NTLAIntellia Therapeutics4.7165 of 5 stars$9.23+0.3%$33.37+261.5%-53.3%$952.96M$57.88M-1.76600News Coverage Related Companies and Tools Related Companies Niagen Bioscience Competitors Aurinia Pharmaceuticals Competitors Enliven Therapeutics Competitors AbCellera Biologics Competitors WAVE Life Sciences Competitors Verve Therapeutics Competitors Phibro Animal Health Competitors Akebia Therapeutics Competitors Collegium Pharmaceutical Competitors Intellia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts